Tweets
« Glucocorticoids are such old drugs and we still use them so much » says Josef Smolen
Summary slide from « 75th anniversary of GCd, what have we learnt? »
@RheumNow #EULAR2024 https://t.co/XSRt44zupw
Aurelie Najm @AurelieRheumo ( View Tweet )
1 year 10 months ago
From the Be-GIANT cohort, 44.3% of patients met the definition of early axSpA (<2 year symptom). The early axSpA group had younger age and lower frequency of radiographic sacroiliitis. Baseline characteristics and disease activity scores at baseline were similar. Physicians… https://t.co/6stDw8sHiI https://t.co/fjINAc4mw3
Links:
Dr. Antoni Chan @synovialjoints ( View Tweet )
1 year 10 months ago
#EULAR2024
@ElenaNikiUK highlights the need to treat the patient not the disease, being cognisant of interacting factors incl #comorbidities
(Don’t think I’ll ever quite get used to seeing my work being referenced on the big screen!)
@RheumNow https://t.co/0tFUR03q8c
Mrinalini Dey @DrMiniDey ( View Tweet )
1 year 10 months ago
THE ASSOCIATION BETWEEN DEPRESSION AND BIOLOGIC PRESCRIBING IN AXIAL SPONDYLOARTHRITIS (axSpA): LESSONS FROM AN IRISH axSpA COHORT more likely to have peripheral arthritis enthesitis psoriasis - shoukd we be formally assessing eg Beck’s DI @RheumNow #EULAR2024
Peter Nash @drpnash ( View Tweet )
1 year 10 months ago
FINDINGS ON MRI OF THE SACROILIAC JOINTS 7 YEARS AFTER PREGNANCY IN WOMEN WITH AND WITHOUT POSTPARTUM BUTTOCK/PELVIC PAIN - source of misdiagnosis but not a cause of progressive lesions @RheumNow #EULAR2024 https://t.co/aEvlkMZtQw
Peter Nash @drpnash ( View Tweet )
1 year 10 months ago
OP0238-HPR: effectiveness of digital patient education programme for RA self-management
Intervention led to improved self-efficacy, w minor improved RA knowledge, #HealthLiteracy & #QoL
➡️such interventions may improve self-management & lower health costs
@RheumNow #EULAR2024
Mrinalini Dey @DrMiniDey ( View Tweet )
1 year 10 months ago
Some of the great questions in ICI-induced irAE pathophysiology, from the great Andy Cope @KingsCollegeLon
#EULAR2024 @RheumNow https://t.co/aHDqnvhboo
David Liew @drdavidliew ( View Tweet )
1 year 10 months ago
🙏🏻I am so grateful for @RheumNow's coverage of our research about radiomics in AxSpA
⭐️I believe radiomics has potential and hope it will become a thing in Rheumatology
👇🏻Here is my interview with @bella_mehta about POS 0236 which I presented at #EULAR2024
https://t.co/yvD9yCIzQ8
Vincenzo Venerito @vincevenerito ( View Tweet )
1 year 10 months ago
DEFINING OVERALL AND SEX-SPECIFIC BASDAI CUT-OFFS FOR DISEASE ACTIVITY STATES IN AXIAL SPONDYLARTHRITIS – RESULTS FROM THE EUROSPA COLLABORATION - more data to stratify for gender at baseline all future AxSpA trials @RheumNow #EULAR2024 https://t.co/nQwCDOxN8R
Peter Nash @drpnash ( View Tweet )
1 year 10 months ago
#EULAR2024 #scleroderma #recommend’ns @eular_org
#lung #ILD
Divide in to
#prevention vs #Rx
#Immune #suppressive #Rx vs
#antifibrotic
My thoughts -?other Rx as ⬆️MR
Likely all effective early #Rx of skin
Improve Risk of
#progression▶️ILD
@EUSTAR_org @RheumNow https://t.co/4wJyeSEHv3
Links:
Janet Pope @Janetbirdope ( View Tweet )
1 year 10 months ago
EFFICACY AND SAFETY OF IXEKIZUMAB IN CHILDREN WITH ACTIVE JUVENILE PSORIATIC ARTHRITIS AND ENTHESITIS RELATED ARTHRITIS (COSPIRIT-JIA): 16-WEEK RESULTS OF A MULTICENTRE, RANDOMISED, OPEN-LABEL STUDY - IL17 effective & safe in JIA @RheumNow #EULAR2024
Peter Nash @drpnash ( View Tweet )
1 year 10 months ago
Izokibep Ph2b/3 RCT PsA 340+
Primary endpoint ACR50 wk 16
IZO 160 mg Q2W 43%
IZO 160 mg QW 40%
PBO 15%
Effect early as wk 4
PASI100
IZO Q2W 47%
IZO QW 51%
PBO 12%
Safety profile similar to IL-17i
@RheumNow #EULAR2024 LBA0005 https://t.co/vWRQ1ECrAX
Aurelie Najm @AurelieRheumo ( View Tweet )
1 year 10 months ago
